Synergism of energy starvation and dextran-conjugated doxorubicin in the killing of multidrug-resistant KB carcinoma cells

被引:7
作者
Lam, W [1 ]
Chan, HL [1 ]
Yang, MS [1 ]
Cheng, SK [1 ]
Fong, WF [1 ]
机构
[1] City Univ Hong Kong, Dept Biol & Chem, Bioact Prod Res Grp, Tat Chee Ave, Kowloon, Peoples R China
关键词
delayed decoupling; dextran-conjugated doxorubicin; multidrug resistance; 2-deoxyglucose/Na azide;
D O I
10.1097/00001813-199902000-00005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Here we report that 2-deoxyglucose/Na azide treatment and free/conjugated doxorubicin are synergistic in cell killing. As demonstrated by fluorescence confocal microscopy, KB-V1 cells retained more conjugated doxorubicin than free doxorubicin. Verapamil or 2-deoxyglucose/Na azide enhanced only the retention of the free drug and the small (<70 kDa) conjugates, indicating that P-glycoprotein (P-gp) is not effective against large conjugates, Conjugated doxorubicin was excluded from nuclei. Initially both free and conjugated doxorubicin accumulated in cytoplasmic organelles. Upon 2-deoxyglucose/Na azide treatment, fluorescence labeling of organelles dissipated, Prolonged (24 h) incubation of conjugate-preloaded cells resulted in redistribution of some of the organelle-associated fluorescence to nuclei, suggesting decoupling, The appearance of free doxorubicin was confirmed by capillary electrophoresis, 2-Deoxyglucose/Na azide treatment also retarded decoupling. Our results suggest that energy starvation, in addition to increasing cellular retention of P-gp substrates, may affect cellular fate of conjugated drugs with a possible enhancing effect in cancer cell killing. [(C) 1999 Lippincott Williams & Wilkins.].
引用
收藏
页码:171 / 178
页数:8
相关论文
共 35 条
[1]  
BARABAS K, 1992, J BIOL CHEM, V267, P9437
[2]  
Bentley J, 1996, ONCOL RES, V8, P77
[3]  
Bogush T, 1996, ANTICANCER RES, V16, P365
[4]  
CHOU J, 1991, SYNERGISM ANTAGONISM, P223
[5]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[6]   The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: Comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines [J].
Consoli, U ;
Priebe, W ;
Ling, YH ;
Mahadevia, R ;
Griffin, M ;
Zhao, S ;
PerezSoler, R ;
Andreeff, M .
BLOOD, 1996, 88 (02) :633-644
[7]   THE MOLECULAR PHARMACOLOGY OF DOXORUBICIN INVIVO [J].
CUMMINGS, J ;
ANDERSON, L ;
WILLMOTT, N ;
SMYTH, JF .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (05) :532-535
[8]   PHASE-I CLINICAL AND PHARMACOKINETIC TRIAL OF DEXTRAN CONJUGATED DOXORUBICIN (AD-70, DOX-OXD) [J].
DANHAUSERRIEDL, S ;
HAUSMANN, E ;
SCHICK, HD ;
BENDER, R ;
DIETZFELBINGER, H ;
RASTETTER, J ;
HANAUSKE, AR .
INVESTIGATIONAL NEW DRUGS, 1993, 11 (2-3) :187-195
[9]  
Fong WF, 1996, ANTICANCER RES, V16, P3773
[10]   STRUCTURE AND FUNCTION OF THE NUCLEAR-PORE COMPLEX [J].
FORBES, DJ .
ANNUAL REVIEW OF CELL BIOLOGY, 1992, 8 :495-527